A detailed history of Northern Trust Corp transactions in Nektar Therapeutics stock. As of the latest transaction made, Northern Trust Corp holds 1,402,158 shares of NKTR stock, worth $1.33 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,402,158
Previous 449,750 211.76%
Holding current value
$1.33 Million
Previous $557,000 227.11%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$1.11 - $1.48 $1.06 Million - $1.41 Million
952,408 Added 211.76%
1,402,158 $1.82 Million
Q2 2024

Aug 14, 2024

BUY
$0.9 - $1.83 $81,547 - $165,812
90,608 Added 25.23%
449,750 $557,000
Q1 2024

May 14, 2024

SELL
$0.49 - $0.96 $32,818 - $64,297
-66,977 Reduced 15.72%
359,142 $334,000
Q4 2023

Feb 13, 2024

BUY
$0.42 - $0.57 $27,801 - $37,730
66,194 Added 18.39%
426,119 $238,000
Q3 2023

Nov 13, 2023

SELL
$0.51 - $1.05 $3,023 - $6,224
-5,928 Reduced 1.62%
359,925 $215,000
Q2 2023

Aug 11, 2023

SELL
$0.53 - $1.03 $751,867 - $1.46 Million
-1,418,618 Reduced 79.5%
365,853 $212,000
Q1 2023

May 15, 2023

SELL
$0.64 - $3.15 $53,147 - $261,585
-83,043 Reduced 4.45%
1,784,471 $1.25 Million
Q4 2022

Feb 13, 2023

BUY
$2.03 - $4.28 $745 - $1,570
367 Added 0.02%
1,867,514 $4.22 Million
Q3 2022

Nov 14, 2022

BUY
$3.04 - $5.14 $2.96 Million - $5.01 Million
974,795 Added 109.24%
1,867,147 $5.98 Million
Q2 2022

Aug 12, 2022

SELL
$3.17 - $6.17 $255,872 - $498,023
-80,717 Reduced 8.3%
892,352 $3.39 Million
Q1 2022

May 13, 2022

SELL
$4.16 - $13.72 $165,875 - $547,071
-39,874 Reduced 3.94%
973,069 $5.25 Million
Q4 2021

Feb 08, 2022

SELL
$10.83 - $18.41 $5.25 Million - $8.92 Million
-484,445 Reduced 32.35%
1,012,943 $13.7 Million
Q3 2021

Nov 15, 2021

BUY
$13.07 - $18.84 $431,911 - $622,586
33,046 Added 2.26%
1,497,388 $26.9 Million
Q2 2021

Aug 13, 2021

SELL
$16.52 - $20.4 $852,597 - $1.05 Million
-51,610 Reduced 3.4%
1,464,342 $25.1 Million
Q1 2021

May 12, 2021

BUY
$16.56 - $25.46 $2.15 Million - $3.3 Million
129,579 Added 9.35%
1,515,952 $30.3 Million
Q4 2020

Feb 11, 2021

SELL
$15.77 - $19.03 $571,205 - $689,285
-36,221 Reduced 2.55%
1,386,373 $23.6 Million
Q3 2020

Nov 16, 2020

SELL
$16.59 - $24.79 $880,613 - $1.32 Million
-53,081 Reduced 3.6%
1,422,594 $23.6 Million
Q2 2020

Aug 14, 2020

BUY
$16.86 - $23.44 $256,626 - $356,780
15,221 Added 1.04%
1,475,675 $34.2 Million
Q1 2020

May 14, 2020

BUY
$14.47 - $27.96 $626,406 - $1.21 Million
43,290 Added 3.05%
1,460,454 $26.1 Million
Q4 2019

Feb 14, 2020

SELL
$15.87 - $23.12 $9.32 Million - $13.6 Million
-587,407 Reduced 29.3%
1,417,164 $30.6 Million
Q3 2019

Nov 13, 2019

BUY
$16.91 - $36.27 $483,473 - $1.04 Million
28,591 Added 1.45%
2,004,571 $36.5 Million
Q2 2019

Aug 13, 2019

BUY
$31.0 - $36.3 $4.29 Million - $5.03 Million
138,524 Added 7.54%
1,975,980 $70.3 Million
Q1 2019

May 13, 2019

BUY
$31.58 - $46.35 $1.36 Million - $1.99 Million
43,012 Added 2.4%
1,837,456 $61.7 Million
Q4 2018

Feb 12, 2019

SELL
$30.43 - $56.65 $104,831 - $195,159
-3,445 Reduced 0.19%
1,794,444 $59 Million
Q3 2018

Nov 14, 2018

BUY
$46.46 - $68.49 $5.78 Million - $8.52 Million
124,331 Added 7.43%
1,797,889 $110 Million
Q2 2018

Sep 18, 2018

SELL
$46.25 - $104.45 $299,792 - $677,044
-6,482 Reduced 0.39%
1,673,558 $81.7 Million
Q2 2018

Aug 14, 2018

SELL
$46.25 - $104.45 $42.8 Million - $96.7 Million
-925,778 Reduced 35.53%
1,680,040 $82 Million
Q1 2018

May 09, 2018

BUY
$57.4 - $108.44 $41.6 Million - $78.5 Million
723,967 Added 38.47%
2,605,818 $277 Million
Q4 2017

Feb 14, 2018

SELL
$23.02 - $60.5 $864,654 - $2.27 Million
-37,561 Reduced 1.96%
1,881,851 $112 Million
Q3 2017

Nov 13, 2017

BUY
$17.79 - $24.0 $34.1 Million - $46.1 Million
1,919,412
1,919,412 $46.1 Million

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $178M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.